Since mid-March, CeGaT has been one of the first companies worldwide to own the brand new NovaSeq™ X Plus, which was announced by Illumina just last fall. Thanks to innovative chemistry and technology, the high-performance sequencer enables an unmatched level of throughput and accuracy: In one run with two flow cells, up to 16 terabases are generated in the shortest possible time. As a result, tens of thousands of genomes can be sequenced yearly. The acquisition of this platform allows CeGaT to meet the increasing demand for molecular genetic analyses and thus make this revolutionary technology available to its customers.
Innovative and sustainable
Dr. Dirk Biskup, managing director, and co-founder of CeGaT, explains, "We look forward to realizing even the most extensive projects in our usual outstanding quality with the NovaSeq™ X Plus. Researchers will be able to complete their studies faster and more efficiently than ever before. The fact that the NovaSeq™ X Plus is also an innovation in ecological terms and saves considerably on resources during operation fits perfectly with our guiding principle of sustainability in all areas of the company."
"We are delighted that CeGaT has taken delivery of one of the first NovaSeq™ X Plus instruments in Europe as it continues to invest to meet the increasing demand for sequencing and genetic analyses," said Bas Verhoef, Head of Region, Europe, Illumina. With its new chemistry, the NovaSeq X series allows our customers to maximize their productivity and minimize turnaround time, that will further our understanding of genetic diseases to improve human health.”
The NovaSeq™ X Plus will be used for a wide range of genomics applications. CeGaT’s business unit, "Research and Pharma Solutions", offers customers from science, pharma, and industry a wide range of sequencing services that are also used in clinical studies under the highest regulatory requirements.
Continuous investment in state-of-the-art technologies
CeGaT continually invests in acquiring the latest technology. The Tübingen-based company recently became the first provider in Germany to acquire PacBio’s Sequel IIe system. The Single Molecule Real-Time (SMRT) technology behind it enables Hi-Fi reads with exceptional accuracy and length. With the acquisition of the NovaSeq™ X Plus, CeGaT underpins its pioneering role in the field of sequencing.
CeGaT GmbH, founded in Tübingen, Germany, in 2009, is a global provider of genetic analyses for a wide range of medical, research, and pharmaceutical applications.
The company combines the latest sequencing technology with its many years of medical expertise – dedicated to identifying the genetic cause of disease and supporting patient care. For research and the pharmaceutical industry, CeGaT offers a broad portfolio of sequencing services and tumor analyses. CeGaT generates the data basis for clinical studies and medical innovations, driving science forward with own findings. The owner-managed company stands for independence, an extensive personal customer service, and premium quality. CeGaT’s laboratory is accredited according to CAP/CLIA, DIN EN ISO 15189, and DIN EN ISO 17025 and thus meets the highest international standards. To keep the responsibility for the whole project, and to maintain the best results, CeGaT carries out all steps in-house and under scientific supervision.
CeGaT GmbH
Paul-Ehrlich-Str. 23
72076 Tübingen
Telefon: +49 7071 565 44 55
Telefax: +49 7071 565 44 56
http://www.cegat.com
Marketing & Communication
Telefon: +49 (7071) 56544-261
E-Mail: christfried.dornis@cegat.de
